Zhang Rui, Lan Junjie, Chen Qi, Liu Yang, Hu Linfang, Cao Jinyong, Zhao Huaye, Shen Yan
Department of Pharmacy, Guizhou Provincial People's Hospital, 550002 Guiyang, China.
Department of Hepatobiliary Surgery II, Guizhou Provincial People's Hospital, 550002 Guiyang, China.
Comb Chem High Throughput Screen. 2024;27(12):1745-1757. doi: 10.2174/1386207326666230803140408.
Acute necrotizing pancreatitis is a serious pancreatic injury with limited effective treatments. This study aims to investigate the therapeutic effects of hesperidin on Larginine- induced acute pancreatitis and its potential targets.
The authors induced acute pancreatitis in mice by administering two hourly intraperitoneal injections of L-arginine-HCl, and evaluated the impact of hesperidin on pancreatic and lung tissues, plasma amylase activity, and myeloperoxidase content. Additionally, necrosis and mitochondrial function was tested in primary pancreatic acinar cells. The interactions between hesperidin and proteins involved in necrosis and mitochondrial dysfunction were further invested using in silico molecular docking and molecular dynamic simulations.
Hesperidin effectively ameliorated the severity of acute necrotizing pancreatitis by reducing plasma amylase, pancreatic MPO, serum IL-6 levels, pancreatic edema, inflammation, and pancreatic necrosis. Hesperidin also protected against acute pancreatitis-associated lung injury and prevented acinar cell necrosis, mitochondrial membrane potential loss, and ATP depletion. In addition, hesperidin exhibited a high binding affinity with SIRT1 and increased the protein levels of SIRT1. The SIRT1 inhibitor EX527 abolished the protective effect of hesperidin against necrosis in acinar cells.
These findings indicate that hesperidin alleviates the severity of acute necrotizing pancreatitis by activating SIRT1, which may provide insight into the mechanisms of natural compounds in treating AP. Hesperidin has potential as a therapeutic agent for acute necrotizing pancreatitis and provides a new approach for novel therapeutic strategies.
急性坏死性胰腺炎是一种严重的胰腺损伤,有效治疗方法有限。本研究旨在探讨橙皮苷对精氨酸诱导的急性胰腺炎的治疗效果及其潜在靶点。
作者通过每两小时腹腔注射L-精氨酸盐酸盐诱导小鼠急性胰腺炎,并评估橙皮苷对胰腺和肺组织、血浆淀粉酶活性及髓过氧化物酶含量的影响。此外,还对原代胰腺腺泡细胞的坏死情况和线粒体功能进行了检测。利用计算机辅助分子对接和分子动力学模拟进一步研究了橙皮苷与参与坏死和线粒体功能障碍的蛋白质之间的相互作用。
橙皮苷通过降低血浆淀粉酶、胰腺MPO、血清IL-6水平、胰腺水肿、炎症及胰腺坏死,有效减轻了急性坏死性胰腺炎的严重程度。橙皮苷还可预防急性胰腺炎相关的肺损伤,并防止腺泡细胞坏死、线粒体膜电位丧失及ATP耗竭。此外,橙皮苷与SIRT1表现出高结合亲和力,并增加了SIRT1的蛋白水平。SIRT1抑制剂EX527消除了橙皮苷对腺泡细胞坏死的保护作用。
这些发现表明橙皮苷通过激活SIRT1减轻急性坏死性胰腺炎的严重程度,这可能为天然化合物治疗急性胰腺炎的机制提供见解。橙皮苷有潜力作为急性坏死性胰腺炎的治疗药物,并为新的治疗策略提供了一种新方法。